Ignite Creation Date:
2025-12-24 @ 4:11 PM
Ignite Modification Date:
2025-12-30 @ 4:27 AM
Study NCT ID:
NCT00023166
Status:
TERMINATED
Last Update Posted:
2005-06-24
First Post:
2001-08-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}], 'ancestors': [{'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C113924', 'term': "poly(ethylene glycol)-conjugated paclitaxel-2'-glycinate"}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2001-05'}, 'statusVerifiedDate': '2004-03', 'completionDateStruct': {'date': '2002-05'}, 'lastUpdateSubmitDate': '2005-06-23', 'studyFirstSubmitDate': '2001-08-24', 'studyFirstSubmitQcDate': '2001-08-25', 'lastUpdatePostDateStruct': {'date': '2005-06-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2001-08-27', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['Phase I', 'Open label', 'Safety/efficacy', 'Lymphomas', 'Advanced primary and/or metastatic solid tumors', 'Neoplasms', 'Neoplasm metastasis'], 'conditions': ['Neoplasm', 'Lymphomas', 'Neoplasm Metastasis']}, 'descriptionModule': {'briefSummary': 'Studies of PEG-paclitaxel have been terminated'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'None - Study has been terminated.'}, 'identificationModule': {'nctId': 'NCT00023166', 'briefTitle': 'Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas', 'organization': {'class': 'INDUSTRY', 'fullName': 'Enzon Pharmaceuticals, Inc.'}, 'officialTitle': 'Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas', 'orgStudyIdInfo': {'id': 'PTX-5001'}}, 'armsInterventionsModule': {'interventions': [{'name': 'PEG-paclitaxel', 'type': 'DRUG'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Enzon Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}}}}